Abstract:Objective To investigate the relationship between IL-6 gene (rs1800796) polymorphism and the clinical features of Parkinson's disease and the prognosis of Madopar treatment.Methods From January 2017 to December 2019, 80 patients with Parkinson's disease (PD group) were collected in our hospital, and 50 healthy volunteers who came to our hospital for physical examination at the same time were selected as the control group. The differences of genotype frequency and allele frequency between the two groups were compared, and the therapeutic effect of different IL-6 genotypes after Madopar treatment was analyzed.Results The percentages of CC wild type and allele C frequency at C-572G site of IL-6 gene (rs1800796) in patients with Parkinson's disease were lower than those in control group, while the frequencies of GG homozygote and allele G were higher than those in control group (P < 0.05). The serum IL-6, UPDRS, PDQ-39, MMSE, and MOCA scores were the lowest in CC group, followed by CG group and the highest in GG group (P < 0.05).Conclusion The effect of Madopar on Parkinson's disease is remarkable. The C-572G polymorphism of IL-6 gene (rs1800796) is closely related to the clinical characteristics of Parkinson's disease and the prognosis of Madopar treatment. Patients with guanine nucleotide (G) mutation have more serious disease condition.